
Digital opportunities will soon be playing a more active role in the research conducted by Denmark’s biggest pharmaceutical firm, Novo Nordisk, which is why the company is establishing a new, global focus area for this purpose.
According to Novo Nordisk, the unit will consist of ”several hundreds of people” and will work with data and and a string of digital tools, including artificial intelligence, in connection with the company’s research and development of new drug candidates.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app